EIB to loan €100m to Pierre Fabre

Published: 16-Dec-2011
Research & Development Finance

To part-finance research into biotherapy projects


The European Investment Bank (EIB) is lending €100m to France’s Laboratoires Pierre Fabre to part-finance pharmaceutical research programmes, particularly for biotherapy.

The company aims to discover new natural, chemical and biological molecules to create treatments for oncology, neuropsychiatry and dermatology.

Projects covered by the EIB loan would include the discovery, preclinical development (such as pharmacokinetics, pharmacology and toxicology) and clinical fields (Phases I, II or III).

Pierre Fabre’s chief executive Jacques Fabre said the loan agreement was a ‘wonderful vote of confidence in our company’s innovative capabilities’.

The EIB’s current lending policy treats research and development loan applications as a priority and this particular financing is covered by the Risk Sharing Finance Facility (RSFF), established jointly in 2007 by the European Commission and the EIB to fuel investment in research, technological development, demonstration and innovation.

Projects financed by this loan will be managed at Pierre Fabre’s main research centres in Toulouse, Saint-Julien-en-Genevois (Haute-Savoie) and Castres (Tarn, southwest France).

  • Companies:
  • Pierre Fabre
See more

You may also like

Media

Cellectar Biosciences and Pierre Fabre collaborate to develop drug conjugates

Read more
Cellectar Biosciences, an oncology-focused, clinical stage biotechnology company, together with French pharmaceutical company Pierre Fabre, will extend its ongoing collaboration to develop new phospholipid drug conjugates (PDCs)

Trending Articles

  1. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  2. Adult vaccination programmes deliver significant socio-economic benefits, study finds The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
  3. Prima BioMed announces new product candidate IMP761: a LAG-3 agonist antibody Prima BioMed announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761
  4. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  5. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Media

Cellectar Biosciences and Pierre Fabre collaborate to develop drug conjugates

Cellectar Biosciences, an oncology-focused, clinical stage biotechnology company, together with French pharmaceutical company Pierre Fabre, will extend its ongoing collaboration to develop new phospholipid drug conjugates (PDCs)
Ingredients

Pierre Fabre signs partnership with SETUBIO as part of the Nature Open Library programme

SETUBIO will explore the plant collection made available by Pierre Fabre to develop new actives for human and animal health
Research & Development

Pierre Fabre and H-Immune launch research partnership to cancer immunotherapies

Focus on solid tumours provides range of possible cancer indications as targets for immuno-oncology therapeutics
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Optimising scale-up with flow process technologies

Speed of synthesis is of the essence when medicinal chemists invent new molecules, reports Sarah Houlton
Research & Development

MATWIN and Pierre Fabre Fund for Innovation strengthen partnership

To boost the development of innovative projects in oncology
Research & Development

Evotec and Pierre Fabre sign five-year compound management agreement

Evotec will handle Pierre Fabre's collection out of its compound management facility in Toulouse
Ingredients

Pierre Fabre and VibioSphen agree new Nature Open Library partnership

Collaboration aims to develop naturally derived compounds to combat antibiotic resistant bacteria
Subscribe now